NN8022-4246 In market utilisation of liraglutide used for weight management in the UK: a study in the CPRD primary care database

First published: 12/04/2018

Last updated: 14/03/2024

Study Finalised

Administrative details

EU PAS number

EUPAS23369

Study ID

50321

DARWIN EU® study

No

Study countries

United Kingdom

Study description

This study is conducted in Europe. The aim of this study is to investigate usage of liraglutide for weight management in clinical practice using the CPRD (Clinical Practice Research Datalink) primary care database.

Study status

Finalised

Research institutions and networks

Institutions

Novo Nordisk

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Contact details

Study institution contact

Clinical Reporting Anchor and Disclosure (1452) Novo Nordisk A/S clinicaltrials@novonordisk.com

Study contact

clinicaltrials@novonordisk.com

Primary lead investigator

Clinical Reporting Anchor and Disclosure (1452) Novo Nordisk A/S

Primary lead investigator

Study timelines

Date when funding contract was signed
Actual: 26/02/2015

Study start date
Planned: 20/04/2018

Actual: 13/04/2018

Date of final study report
Planned: 31/07/2023

Actual: 31/07/2023

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

Novo Nordisk A/S

Study protocol

4246-protocol-redacted.pdf (394.99 KB)

4246-protocol-eu-pas-reg-redacted.pdf (408.12 KB)

Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)

Other study registration identification numbers and links

UTN: U1111-1185-3276,NCT: NCT03479762

Methodological aspects

Study type

Study type list

Study type:

Non-interventional study

Scope of the study:

Drug utilisation

Main study objective:

The aim of this study is to investigate usage of liraglutide for weight management in clinical practice using the CPRD (Clinical Practice Research Datalink) primary care database

Study Design

Non-interventional study design

Cohort

Study drug and medical condition

Study drug International non-proprietary name (INN) or common name

LIRAGLUTIDE

Medical condition to be studied

Obesity

Population studied

Age groups

- Adults (18 to < 46 years)
- Adults (46 to < 65 years)
- Adults (65 to < 75 years)
- Adults (75 to < 85 years)
- Adults (85 years and over)

Estimated number of subjects

200

Study design details

Outcomes

Acc. to protocol section 6.3.1, Acc. to study protocol section 6.3.2

Data analysis plan

All data analysis will be performed by CPRD. Information from the CPRD primary care database and from the questionnaires will be used to present descriptive statistics of the proportion of patients with the endpoints of interest.

Documents

Study results

4246 nsr nn-trials redacted.pdf (2.37 MB)

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data source(s)

Clinical Practice Research Datalink

Data sources (types)

Electronic healthcare records (EHR)

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No